Ranbaxy Laboratories is being prohibited by FDA from manufacturing and distributing active pharmaceutical ingredients (APIs) from its Toansa, India, facility in order “to prevent substandard quality products from reaching U.S. consumers,” according to a news release.
Ranbaxy Laboratories is being prohibited by FDA from manufacturing and distributing active pharmaceutical ingredients (APIs) from its Toansa, India, facility in order “to prevent substandard quality products from reaching U.S. consumers,” according to a news release.
The agency inspected the Toansa facility in mid-January and found significant violations of current good manufacturing practice (CGMP) requirements. Staff of the facility had retested raw materials, intermediate drug products, and finished API after they had already failed analytical testing and specifications. The staff members wanted to produce acceptable findings and did not report or investigate the failures, according to FDA.
“Ranbaxy will not be permitted to resume manufacturing and distributing API for FDA-regulated drugs from the Toansa facility until the agency is satisfied that Ranbaxy has addressed its manufacturing quality issues at that facility,” FDA noted.
A third-party expert must be used to inspect the Toansa facility at Ranbaxy’s expense in order to certify that the facility is in compliance with CGMP.
For additional information on FDA’s regulatory activities for Ranbaxy, go to FDA’s website.
FDA Issues Complete Response for High-Dose Opioid Rescue Med
July 16th 2024OX124 is a nasal spray provides rapid absorption of naloxone for patients experiencing an opioid overdose. The FDA would like to see additional technical data, as well as data on whether patients can correctly use the device.
Read More